Equities research analysts expect Galápagos NV (NASDAQ:GLPG) to announce $51.73 million in sales for the current fiscal quarter, Zacks reports. Two analysts have made estimates for Galápagos’ earnings, with estimates ranging from $47.80 million to $55.66 million. Galápagos reported sales of $36.45 million in the same quarter last year, which would suggest a positive year over year growth rate of 41.9%. The firm is scheduled to announce its next quarterly earnings results on Monday, July 30th.
According to Zacks, analysts expect that Galápagos will report full-year sales of $238.95 million for the current financial year, with estimates ranging from $200.92 million to $286.77 million. For the next fiscal year, analysts forecast that the business will post sales of $221.38 million per share, with estimates ranging from $155.02 million to $265.84 million. Zacks Investment Research’s sales averages are a mean average based on a survey of sell-side analysts that follow Galápagos.
Galápagos (NASDAQ:GLPG) last released its quarterly earnings data on Wednesday, April 25th. The biotechnology company reported ($0.90) EPS for the quarter, beating the consensus estimate of ($1.20) by $0.30. The company had revenue of $55.04 million during the quarter, compared to the consensus estimate of $44.77 million. Galápagos had a negative return on equity of 14.06% and a negative net margin of 86.32%.
Several research firms have recently commented on GLPG. Zacks Investment Research raised Galápagos from a “sell” rating to a “hold” rating in a report on Wednesday, May 2nd. ValuEngine raised Galápagos from a “sell” rating to a “hold” rating in a report on Friday, February 2nd. BTIG Research reissued a “buy” rating and issued a $118.00 price objective on shares of Galápagos in a report on Sunday, April 29th. Finally, BidaskClub downgraded Galápagos from a “hold” rating to a “sell” rating in a report on Tuesday, May 1st. One equities research analyst has rated the stock with a sell rating, four have assigned a hold rating and six have assigned a buy rating to the stock. Galápagos presently has an average rating of “Hold” and a consensus target price of $111.00.
A number of institutional investors have recently made changes to their positions in GLPG. Financial Gravity Companies Inc. acquired a new stake in Galápagos during the 4th quarter valued at $104,000. Tower Research Capital LLC TRC lifted its holdings in Galápagos by 7,340.0% during the 4th quarter. Tower Research Capital LLC TRC now owns 1,488 shares of the biotechnology company’s stock valued at $140,000 after purchasing an additional 1,468 shares during the last quarter. Envestnet Asset Management Inc. lifted its holdings in Galápagos by 32.9% during the 4th quarter. Envestnet Asset Management Inc. now owns 2,315 shares of the biotechnology company’s stock valued at $217,000 after purchasing an additional 573 shares during the last quarter. Advisor Group Inc. lifted its holdings in Galápagos by 23.4% during the 4th quarter. Advisor Group Inc. now owns 3,492 shares of the biotechnology company’s stock valued at $327,000 after purchasing an additional 663 shares during the last quarter. Finally, Atria Investments LLC lifted its holdings in Galápagos by 23.0% during the 4th quarter. Atria Investments LLC now owns 3,609 shares of the biotechnology company’s stock valued at $338,000 after purchasing an additional 676 shares during the last quarter. 19.42% of the stock is owned by institutional investors and hedge funds.
Galápagos opened at $95.47 on Friday, according to Marketbeat Ratings. Galápagos has a 12 month low of $93.63 and a 12 month high of $95.78.
Galapagos NV, a clinical-stage biotechnology company, discovers, develops, and commercializes novel medicines. Its clinical stage programs include filgotinib, which is in Phase III clinical trials for the treatment of rheumatoid arthritis and Crohn's disease, Phase 2/3 trials for ulcerative colitis, and Phase II trials for multiple additional indications; GLPG1690, an autotaxin inhibitor, which is in Phase III clinical trial for the treatment of idiopathic pulmonary fibrosis; GLPG1972 that completed Phase 1b clinical trial for the treatment of osteoarthritis; and MOR106, which is in Phase II trials for atopic dermatitis patients.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Galápagos Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Galápagos and related companies with MarketBeat.com's FREE daily email newsletter.